Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in Thoracic Carcinoma and Translational Research
share announcement

Advances in Thoracic Carcinoma and Translational Research

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (15 November 2023) | Viewed by 5489

Special Issue Editors

Dr. Jiangyong Yu

E-Mail Website
Guest Editor
1. Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Beijing, China
2. Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
Interests: novel therapy strategies, biomarkers and translational research in thoracic carcinoma
Dr. Jun Zhao

E-Mail Website
Guest Editor
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing, China
Interests: multidisciplinary comprehensive treatment of lung cancer
Dr. Jie Ma

E-Mail Website
Guest Editor
Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
Interests: gastrointestinal tumors; tumor immunotherapy; anti-tumor nano-drug research
Dr. Jia Zhong

E-Mail Website
Guest Editor
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Interests: lung cancer; pleural mesothelioma

Special Issue Information

Dear Colleagues,

This Special Issue will focus on the significant progress in the treatments, biomarkers and translational research of thoracic carcinoma in recent years, including original articles and reviews of the new standard of care for lung cancer as well as rarer cancers such as mesothelioma and thymic neoplasms. Just as important are the challenges that remain to be overcome. In this issue, we will focus on the diagnosis and therapy of patients with lung cancer, advances in targeted therapy, immunotherapy and also ADC drugs in patients with lung cancer, and the new diagnosis strategies and biomarkers in patients with lung cancer and other thoracic carcinomas, the optimization of first- and second-line treatment for patients with small cell lung cancer, translational researches in lung cancer and other thoracic carcinomas,  and the selection of chemotherapy or immunotherapy for patients with mesothelioma and thymic neoplasms. We will also address areas of ongoing research including immune-related toxicities and attempts to overcome resistance to chemotherapy and immunotherapy.

In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.

Dr. Jiangyong Yu
Dr. Jun Zhao
Dr. Jie Ma
Dr. Jia Zhong
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • immunotherapy
  • immune checkpoint inhibitors (ICI)
  • non-small cell lung cancer (NSCLC)
  • small cell lung cancer (SCLC)
  • thoracic carcinoma
  • biomarkers
  • translational research
  • targeted therapy
  • immune related toxicities
  • resistance
  • mesothelioma
  • thymic neoplasms

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 4055 KiB  
Article
Continuous Relationship of Operative Duration with Risk of Adverse Perioperative Outcomes and Early Discharge Undergoing Thoracoscopic Lung Cancer Surgery
by Chaoyang Tong, Yaofeng Shen, Hongwei Zhu, Jijian Zheng, Yuanyuan Xu and Jingxiang Wu
Cancers 2023, 15(2), 371; https://doi.org/10.3390/cancers15020371 - 6 Jan 2023
Cited by 3 | Viewed by 1438
Abstract
Background: For thoracoscopic lung cancer surgery, the continuous relationship and the trigger point of operative duration with a risk of adverse perioperative outcomes (APOs) and early discharge remain unknown. Methods: This study enrolled 12,392 patients who underwent this surgical treatment. Five groups were [...] Read more.
Background: For thoracoscopic lung cancer surgery, the continuous relationship and the trigger point of operative duration with a risk of adverse perioperative outcomes (APOs) and early discharge remain unknown. Methods: This study enrolled 12,392 patients who underwent this surgical treatment. Five groups were stratified by operative duration: <60 min, 60–120 min, 120–180 min, 180–240 min, and ≥240 min. APOs included intraoperative hypoxemia, delayed extubation, postoperative pulmonary complications (PPCs), prolonged air leakage (PAL), postoperative atrial fibrillation (POAF), and transfusion. A restricted cubic spline (RCS) plot was used to characterize the continuous relationship of operative duration with the risk of APOs and early discharge. Results: The risks of the aforementioned APOs increased with each additional hour after the first hour. A J-shaped association with APOs was observed, with a higher risk in those with prolonged operative duration compared with those with shorter values. However, the probability of early discharge decreased from 0.465 to 0.350, 0.217, and 0.227 for each additional hour of operative duration compared with counterparts (<60 min), showing an inverse J-shaped association. The 90 min procedure appears to be a tipping point for a sharp increase in APOs and a significant reduction in early discharge. Conclusions: Our findings have important and meaningful implications for risk predictions and clinical interventions, and early rehabilitation, for APOs. Full article
(This article belongs to the Special Issue Advances in Thoracic Carcinoma and Translational Research)
►▼ Show Figures

Figure 1

10 pages, 501 KiB  
Article
Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial
by Andrea Camerini, Alessandro Del Conte, Aldo Pezzuto, Vieri Scotti, Francesco Facchinetti, Lucia Pia Ciccone, Marco Perna, Giulia Sartori, Cheti Puccetti, Alberto Ricci, Antonio Santo, Marcello Tiseo and Domenico Amoroso
Cancers 2022, 14(24), 6074; https://doi.org/10.3390/cancers14246074 - 9 Dec 2022
Cited by 2 | Viewed by 1617
Abstract
Limited evidence is available concerning the selection criteria and the outcomes of platinum unfit newly diagnosed advanced NSCLC patients receiving single-agent chemotherapy. We retrospectively collected data on consecutive, stage IIIB-IV, EGFR/ALK negative and PD-L1 < 50% NSCLC patients treated with first-line single agent [...] Read more.
Limited evidence is available concerning the selection criteria and the outcomes of platinum unfit newly diagnosed advanced NSCLC patients receiving single-agent chemotherapy. We retrospectively collected data on consecutive, stage IIIB-IV, EGFR/ALK negative and PD-L1 < 50% NSCLC patients treated with first-line single agent chemotherapy. Baseline characteristics, outcome measures and toxicities were recorded, as well as criteria according to which treatment selection was made and what percentage of patients did not receive a first-line platinum-based chemotherapy. Two-hundred and twenty-one patients were included. Median age was 79 (range 56–92) years, M/F 165(74.6%)/56(25.4%), ECOG performance status (PS) 0/1/ ≥ 2 23(10.9%)/94(42.5%)/103(46.6%), with a median of two serious comorbidities. A median of 25% (range 10%-30%) of newly diagnosed NSCLC did not receive a first-line platinum combination. Clinical criteria according to which decision was made were older age (76.5%), comorbidities (72%), poor PS (55.2%) and familiar or social issues (10%). Single-agent treatment consisted of oral metronomic vinorelbine (MetV 78.6%), gemcitabine (Gem 10%), oral standard vinorelbine (Vin 8.2%) and other (O 3.2%). Median progression-free survival (PFS) and overall survival (OS) of single agent treatments ranged from 4.5 to 5 months and from 9 to 10.5 months, respectively. All grade toxicities did not differ among single agents, while grade 3–4 toxicities were less frequent with MetV. Up to 30% of newly diagnosed advanced EGFR/ALK negative and PD-L1 < 50% NSCLC patients do not receive a first-line platinum doublet. Main clinical selection criteria were older age (>70 years), comorbidities and poor PS. An oral treatment was frequently proposed with MetV being the most frequent choice according to its safety profile. Full article
(This article belongs to the Special Issue Advances in Thoracic Carcinoma and Translational Research)
►▼ Show Figures

Figure 1

15 pages, 3152 KiB  
Article
Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
by Yiting Dong, Yixiang Zhu, Minglei Zhuo, Xiaomin Chen, Yinpeng Xie, Jianchun Duan, Hua Bai, Shiguang Hao, Zicheng Yu, Yuting Yi, Yanfang Guan, Jie Yuan, Xuefeng Xia, Xin Yi, Jie Wang and Zhijie Wang
Cancers 2022, 14(22), 5649; https://doi.org/10.3390/cancers14225649 - 17 Nov 2022
Cited by 4 | Viewed by 1559
Abstract
Introduction: Recent studies exhibited the unstable prediction ability of blood-based tumor mutational burden (bTMB) when predicting the response of immune checkpoint inhibitors (ICIs) therapy in patients with non-small cell lung cancer (NSCLC). Circulating tumor DNA (ctDNA) abundance, usually represented by maximum somatic allele [...] Read more.
Introduction: Recent studies exhibited the unstable prediction ability of blood-based tumor mutational burden (bTMB) when predicting the response of immune checkpoint inhibitors (ICIs) therapy in patients with non-small cell lung cancer (NSCLC). Circulating tumor DNA (ctDNA) abundance, usually represented by maximum somatic allele frequency (MSAF), was one possible confounding factor influencing bTMB ability in ICIs response prediction. Methods: MSAF-adjusted bTMB (Ma-bTMB) was established and validated in patients with advanced NSCLC among Geneplus Cancer Genome Database (GCGD, n = 1679), Zhuo (n = 35), Wang (n = 45), POPLAR (NCT01903993, n = 211) and OAK (NCT02008227, n = 642) cohorts. Results: MSAF demonstrated a modest positive correlation with bTMB and a negative one with survival benefit. Improved survival outcomes of ICIs therapy have been observed among patients with high-Ma-bTMB compared to those with low-Ma-bTMB in Zhuo and Wang cohorts. In addition, compared to low-Ma-bTMB, high-Ma-bTMB was associated with more positive clinical benefits from ICIs therapy than chemotherapy both in POPLAR and OAK cohorts. Further exploration suggested that Ma-bTMB could precisely identify more potential ICIs beneficiaries compared to bTMB and LAF-bTMB, complementary to PD-L1 expression. Conclusions: We developed Ma-bTMB, a convenient, readily available, non-invasive predictive biomarker effectively differentiates beneficiaries of ICIs therapy in advanced NSCLC, warranting future clinical trials. Full article
(This article belongs to the Special Issue Advances in Thoracic Carcinoma and Translational Research)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop